PharmTech Poll Results: OTC Children’s Medications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmTech Poll Results: OTC Children’s Medications


Untitled Document

PharmTech Poll Results: OTC Children’s Medications

The question:

The US Food and Drug Administration’s Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee recently recommended that over-the-counter cough and cold medications not be given to children under age 6 based on their conclusion that the drugs have not been proven effective according to current research and there is a risk of adverse effects. The committees further recommended that dosing devices be required and standardized using volume measurements for liquid formulations.

Do you agree with the committees that there should be standardized dosing devices for all OTC children’s medications?

Your Answers:

Thanks to all of you who participated in our poll! All respondants agreed that OTC children’s medications should have standardized dosing devices.

One person commented, “These should be sold directly by the pharmacist like the pseudoephedrine formulations so the parents administering the doses understand how to use the dosing device and to make sure the patient is not taking other medication that could impact the dosing.”

To add your comments, click here.

For more on this topic, see:

Wyeth Recalls Cold Medicines, Lawmakers Urge FDA Action

FDA Committees Recommend Ban on Cough and Cold Medications for Young Children

Drug Makers Voluntarily Recall OTC Infant Cough and Cold Medications

FDA to Discuss Pediatric OTC Drugs, Warns Against Codeine Use

To see the results of our previous polls, see the poll archive.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here